FDA Set to Approve Arcutis' Zoryve for Pediatric Plaque Psoriasis

The U.S. Food and Drug Administration is poised to deliver a pivotal decision regarding Arcutis Biotherapeutics' Zoryve cream (roflumilast) for the treatment of plaque psoriasis in children aged 2 to 5. With the regulatory action date scheduled for late June, industry analysts and healthcare providers anticipate a favorable outcome that would address a significant unmet need for this vulnerable age group. The potential approval comes as the agency reviews the supplemental application seeking to expand the drug's indication to younger patients.

If approved, Zoryve would offer a novel topical treatment option specifically tailored for pediatric use, leveraging its anti-inflammatory properties to manage the chronic skin condition effectively. The decision is highly awaited by dermatologists who have limited therapeutic choices for toddlers and young children suffering from moderate to severe plaque psoriasis. The regulatory green light would mark a significant milestone for Arcutis, solidifying its footprint in the dermatology market and providing relief for families seeking safe and effective solutions for early childhood skin diseases.